Dr. Reynolds Delgado, M.D.
What this data tells you about Dr. Delgado
Dr. Reynolds Delgado is a cardiovascular disease in Houston, TX, with 19 years in practice. Based on federal Medicare data, Dr. Delgado performed 4,450 Medicare services across 1,620 unique beneficiaries.
Between the years covered by Open Payments, Dr. Delgado received a total of $475,349 from 59 pharmaceutical and/or device companies across 1417 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Delgado is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) | 1,662 | $0 | $4 |
| Remote patient monitoring management, 20 min/month | 332 | $39 | $128 |
| Remote patient monitoring device, 30 days | 331 | $40 | $128 |
| Electrocardiogram (EKG), 12-lead | 320 | $12 | $76 |
| Echocardiogram, transthoracic | 272 | $155 | $1,250 |
| Office visit, established patient (30-39 min) | 254 | $97 | $205 |
| Hospital follow-up visit, moderate complexity | 208 | $64 | $137 |
| Regadenoson injection (Lexiscan) for heart stress test | 184 | $42 | $69 |
| Telephone medical discussion with physician, 11-20 minutes | 161 | $71 | $133 |
| Evaluation of lower heart chamber assist device | 100 | $32 | $145 |
| Hospital follow-up visit, high complexity | 96 | $96 | $195 |
| Office visit, established patient (20-29 min) | 73 | $69 | $133 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 72 | $51 | $266 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 58 | $355 | $2,000 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 58 | $89 | $114 |
| Initial hospital admission, high complexity | 44 | $140 | $385 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 28 | $9 | $14 |
| Telephone medical discussion with physician, 5-10 minutes | 28 | $43 | $96 |
| New patient office visit (45-59 min) | 26 | $125 | $342 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 24 | $41 | $64 |
| Office visit, established patient (10-19 min) | 23 | $46 | $96 |
| Ultrasonic guidance for blood vessel access | 21 | $20 | $240 |
| Cardiac catheterization | 21 | $428 | $8,002 |
| Ultrasound of both sides of head and neck blood flow | 16 | $151 | $600 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 13 | $1,009 | $3,395 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 13 | $582 | $852 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 12 | $287 | $1,508 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (96%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in cardiovascular disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for cardiovascular disease in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Delgado is a clinical cardiology specialist, with above-average Medicare volume (top 21% in TX), and high industry engagement (speaking/promotional, top 1%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Delgado experienced with contrast dye for imaging (iodine-based)?
Does Dr. Delgado receive payments from pharmaceutical companies?
How do Dr. Delgado's costs compare to other cardiovascular diseases in Houston?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology